Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics

MAbs. 2022 Jan-Dec;14(1):2020082. doi: 10.1080/19420862.2021.2020082.


Therapeutic monoclonal antibodies and their derivatives are key components of clinical pipelines in the global biopharmaceutical industry. The availability of large datasets of antibody sequences, structures, and biophysical properties is increasingly enabling the development of predictive models and computational tools for the "developability assessment" of antibody drug candidates. Here, we provide an overview of the antibody informatics tools applicable to the prediction of developability issues such as stability, aggregation, immunogenicity, and chemical degradation. We further evaluate the opportunities and challenges of using biopharmaceutical informatics for drug discovery and optimization. Finally, we discuss the potential of developability guidelines based on in silico metrics that can be used for the assessment of antibody stability and manufacturability.

Keywords: antibody engineering; biopharmaceutical informatics; computational prediction; developability assessment; developability guidelines; therapeutic antibodies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review
  • Video-Audio Media

MeSH terms

  • Antibodies, Monoclonal*
  • Biological Products*
  • Computer Simulation*
  • Drug Discovery*
  • Humans


  • Antibodies, Monoclonal
  • Biological Products

Grants and funding

This work was supported by the Engineering and Physical Sciences Research Council [EP/N024796/1]; Royal Society [URF\R1\201461].